These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1879047)

  • 21. Anthracycline antibiotics in cancer therapy. Focus on drug resistance.
    Booser DJ; Hortobagyi GN
    Drugs; 1994 Feb; 47(2):223-58. PubMed ID: 7512899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
    Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BW; Ejlertsen B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BV
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):13-8. PubMed ID: 8629030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer.
    Twelves CJ; Dobbs NA; Aldhous M; Harper PG; Rubens RD; Richards MA
    Cancer Chemother Pharmacol; 1991; 28(4):302-7. PubMed ID: 1879047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer.
    Swenson CE; Bolcsak LE; Batist G; Guthrie TH; Tkaczuk KH; Boxenbaum H; Welles L; Chow SC; Bhamra R; Chaikin P
    Anticancer Drugs; 2003 Mar; 14(3):239-46. PubMed ID: 12634619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit.
    Cusack BJ; Young SP; Driskell J; Olson RD
    Cancer Chemother Pharmacol; 1993; 32(1):53-8. PubMed ID: 8462124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
    Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
    Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion.
    Muller C; Chatelut E; Gualano V; De Forni M; Huguet F; Attal M; Canal P; Laurent G
    Cancer Chemother Pharmacol; 1993; 32(5):379-84. PubMed ID: 8339389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients.
    Robert J; David M; Huet S; Chauvergne J
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1289-94. PubMed ID: 3181250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity.
    Chlebowski RT; Paroly WS; Pugh RP; Hueser J; Jacobs EM; Pajak TF; Bateman JR
    Cancer Treat Rep; 1980 Jan; 64(1):47-51. PubMed ID: 7379058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pharmacokinetic analysis program (multi) for microcomputer.
    Yamaoka K; Tanigawara Y; Nakagawa T; Uno T
    J Pharmacobiodyn; 1981 Nov; 4(11):879-85. PubMed ID: 7328489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
    Legha SS; Benjamin RS; Mackay B; Ewer M; Wallace S; Valdivieso M; Rasmussen SL; Blumenschein GR; Freireich EJ
    Ann Intern Med; 1982 Feb; 96(2):133-9. PubMed ID: 7059060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of prior therapy on plasma levels of adriamycin during subsequent therapy.
    Gessner T; Robert J; Bolanowska W; Hoerni B; Durand M; Preisler H; Rustum J
    J Med; 1981; 12(2-3):183-93. PubMed ID: 6944425
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response.
    Robert J; Illiadis A; Hoerni B; Cano JP; Durand M; Lagarde C
    Eur J Cancer Clin Oncol; 1982 Aug; 18(8):739-45. PubMed ID: 6891324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age dependence of the early-phase pharmacokinetics of doxorubicin.
    Robert J; Hoerni B
    Cancer Res; 1983 Sep; 43(9):4467-9. PubMed ID: 6871877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early-phase pharmacokinetics of doxorubicin in non-Hodgkin lymphoma patients. Dose-dependent and time-dependent pharmacokinetic parameters.
    Robert J; Hoerni B; Vrignaud P; Lagarde C
    Cancer Chemother Pharmacol; 1983; 10(2):115-9. PubMed ID: 6831624
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.